Moleculin Biotech Capital Expenditures (CapEx) Growth & History (MBRX)

Moleculin Biotech's capital expenditures (capex) was $0 for fiscal 2025.

View full Moleculin Biotech company overview

Moleculin Biotech annual capital expenditures (capex) history

Moleculin Biotech annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20252025-12-31$0−$13,000
20242024-12-31$13,000−$111,000−89.52%
20232023-12-31$124,000$57,000+85.07%
20222022-12-31$67,000$48,000+252.63%
20212021-12-31$19,000−$357,000−94.95%
20202020-12-31$376,000$324,000+623.08%
20192019-12-31$52,000−$365,000−87.53%
20182018-12-31$417,000$389,000+1389.29%
20172017-12-31$28,000$7,000+33.33%
20162016-12-31$21,000

Moleculin Biotech capital expenditures (capex) trends

Over the last five fiscal years, Moleculin Biotech's capital expenditures (capex) decreased from $376,000 to $0, a change of −$376,000. The latest reported quarter, Q4 2025, shows $0.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

SEC-reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Moleculin Biotech source filings ↗

Community posts

It’s quiet here.

No posts about MBRX yet. Start the conversation.

Write the first post